acetylcarnitine has been researched along with Parkinson Disease, Secondary in 2 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| " ALC (200mg/kg) lowered apomorphine-induced rotational asymmetry and reduced the latency to initiate and the total time in the narrow beam test, reduced striatal malondialdehyde (MDA), increased catalase activity and glutathione (GSH) level, prevented reduction of nigral tyrosine hydroxylase (TH)-positive neurons and striatal TH-immunoreactivity, and lowered striatal glial fibrillary acidic protein (GFAP) and its immunoreactivity as an indicator of astrogliosis, and nuclear factor NF-kappa B and Toll-like receptor 4 (TLR4) as reliable markers of neuroinflammation." | 3.85 | Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat. ( Afshin-Majd, S; Baluchnejadmojarad, T; Bashiri, K; Kiasalari, Z; Roghani, M; Sedaghat, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshin-Majd, S | 1 |
| Bashiri, K | 1 |
| Kiasalari, Z | 1 |
| Baluchnejadmojarad, T | 1 |
| Sedaghat, R | 1 |
| Roghani, M | 1 |
| Bodis-Wollner, I | 1 |
| Chung, E | 1 |
| Ghilardi, MF | 1 |
| Glover, A | 1 |
| Onofrj, M | 1 |
| Pasik, P | 1 |
| Samson, Y | 1 |
2 other studies available for acetylcarnitine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Topics: Acetylcarnitine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine Agonists; Dopamin | 2017 |
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.
Topics: Acetylcarnitine; Animals; Carbidopa; Caudate Nucleus; Electroretinography; Female; Homovanillic Acid | 1991 |